References
- Litzow MR, Othus M, Cripe LD, . Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 2009;148:217–225.
- Armistead PM, de Lima M, Pierce S, . Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009;15:1431–1438.
- Blum W, Bolwell BJ, Phillips G, . High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006;12:61–67.
- Duval M, Klein JP, He W, . Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010;28:3730–3738.
- Larson RA, Sievers EL, Stadtmauer EA, . Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442–1452.
- Chevallier P, Prebet T, Turlure P, . Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2009;45:165–170.
- de Lima M, Champlin RE, Thall PF, . Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008;22:258–264.
- Piccaluga PP, Martinelli G, Rondoni M, . First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28:987–990.
- Chevallier P, Delaunay J, Turlure P, . Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008;26:5192–5197.
- Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
- Simon M, Hahn T, Ford LA, . Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001;27:627–633.
- Bearman SI, Anderson GL, Mori M, . Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729–1736.
- Przepiorka D, Weisdorf D, Martin P, . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–828.
- Lee SJ, Vogelsang G, Gilman A, . A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002;8:32–39.
- Platzbecker U, Thiede C, Fussel M, . Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006;20: 707–714.